Table 1.
Mechanism of squamous cell carcinoma pathogenesis within proteomic analysis.
| Type of disease | Sample | TOP differential proteins | Biological process of cancer | Highlighting mechanism | Depth mechanism | Ref. |
|---|---|---|---|---|---|---|
| SCC | SCC cell lines | ANO1, CE350, NRBF2, NSUN4, K1C14, KT33B, HORN in 10% O2; TRI18, TRY3, ZN714, VAT1, AL1B1 in 5% O2; TRFL, HBA, PI3R4, CTL1, K2C8, TTLL1, FGFR2, DKK2, CCD73, STON2, SHRM3 in 1% O2 | Levels of hypoxia | Energy, metabolism, nucleic acid regulation | — | Głuszko et al. (2021) |
| SCC | SCC cell lines | Up: CK19, tropomyosin 1α chain, HSP27, CK8, AHCY, NNMT, GSTO1 | Proliferation, invasion (NNMT) | — | NNMT knockdown inhibits cell migration and invasion | Hah et al. (2019) |
| SCC | SCC cell lines | A431: FUCA2, LRG1, MAGEA4, CSF1, PROS1, PLAT, LCP1, AXL, EGFR, DNAJB11; | — | Metabolism, mTOR, PI3K-AKT, RAP1 signaling | Secretome of A431 cancer cells accelerates migration and proliferation | Hoesl et al. (2020) |
| HaCaT: SERPINB7, MMP13, GSN, DSG4, MXRA5, SEMA3A, FN1, SPARC, MMP2, DSC3 | ||||||
| SCC | SCC cell lines | Down: AKT2, MAP4K4, PRKCD, ERBB2, CLK2, STK10, MAP2K1, EGFR, PTK2B, MAP2K2; | Invasion | MAPK, mTOR pathways; adhesions, skeleton | YAP1 and SOX2 are related to mesenchymal and epithelial transcriptional programs | Pastushenko et al. (2021) |
| Up: YES1, CDK11, PRPF4B, BMP2K, CDK12, PNKP, MNAT, MINK | ||||||
| SCC | SCC cell lines | Up: FABP5, S100A9, S100A8, SPRR1A, AKR1C3, AKR1C2, SPRR1B | Proliferation | — | — | Shintani et al. (2021) |
| SCC | SCC cell lines | CDK1T14,Y15, EIF4EBP1T46,T50, EIF4BS422, AKT1S1T246,S247, CTTN1T401,S405,Y421, CAP1S307/309 in K8-S73A/D mutant; CTTN1T401,S405,Y421, BUB1BS1043, CARHSP1S30,S32 in K8-S431A/D mutant | Metastasis, Proliferation, Invasion | Junction, JNK/SAPK, CDC42 signaling, Hippo signaling | — | Tiwari et al. (2017) |
| SCC | SCC cell lines | — | — | Cholesterol and steroid metabolic process | HMGCS1 partly was related to A431 cell proliferation | Xu et al. (2022) |
| SCC | SCC cell lines | KRT8, KRT14, KRT18 | — | — | — | Yamashiro et al. (2010) |
| SCC | SCC cell lines | — | — | — | — | Yanagi et al. (2018) |
| SCC | Human [SCC (n = 5)] | Up: G3BP, Filamin-A, NDRG1, Myosin-9, Plectin, 40S Ribosomal protein S4, Actin-related protein 2/3 complex subunit 1B, Fascin, Transgelin, Superoxide dismutase [Mn]; | — | Cell survival, proliferation | — | Azimi et al. (2016) |
| Down: FLG2, Suprabasin, FLG, Dermokine, Apolipoprotein EArginase-1, Galectin-7, Desmoglein-1, Desmoplakin, Collagen alpha-1(III) chain, Corneodesmosin | ||||||
| SCC | Human [SCC (n = 20)] | — | — | Gene, metabolism | — | Chen et al. (2021) |
| SCC | Human [samples of primary (n = 19 patients, n = 20 lesions) and metastatic SCC lesions (n = 20 patients, 25 lesions)] | Up: ISG15 ubiquitin like modifier, APOA1, MARCKS, EFHD2, STMN1, ACBD3; | Metastasis | Invasion, migration, immune response | — | Azimi et al. (2020) |
| Down: CMA1, CST6, KRT79, CPA3, APCS, DMKN | ||||||
| SCC | Human [primary (n = 52), metastasize (n = 53)] | Up: TNC, POSTN, TGFB1, PRDX5, SFPQ, FGB, LCP1, PHB2, HNRNPA2B1, P4HB; | Metastasis | PI3K-Akt signaling | — | Shapanis et al. (2021) |
| Down: CALML5, KRT2, KRT6B | ||||||
| SCC | Human [AK (n = 19), SCC (n = 21), HCs (n = 40)] | — | — | MEK-ERK, EGFR, mTOR pathways | — | Einspahr et al. (2021) |
| SCC | Human | — | — | Cell motility, cell death, survival, growth, proliferation, morphology | KRT17 protein is related to caspase-mediated degradation, supporting by altered TMS1-NF-κB signaling | Tiwari et al. (2018) |
SCC: squamous cell carcinoma; HCs, human controls; AK, actinic keratosis; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; mTOR, mechanistic target of rapamycin; JNK/SAPK, c-Jun N-terminal kinase/stress-activated protein kinase; CDC42, cell division cycle 42; RAP1, role of ras-associated protein 1; EGFR, epidermal growth factor receptor; Panx1, pannexin 1; AKT, protein kinase B; NNMT, N-nicotinamide methyltransferase; YAP1, yes-associated protein 1; SOX2, SRY-box transcription factor 2; HMGCS1, 3-hydroxy-3-methylglutaryly-CoA synthase 1; NF-κB, nuclear factor-kappaB; KRT17, keratin 17; AKT2, AKT serine/threonine kinase 2; CLK2, cdc2-like kinase 2; MAP2K1, mitogen-activated protein kinase kinase 1; MAP4K4, mitogen-activated protein kinase kinase kinase kinase 4; PRKCD, protein kinase C, delta; ERBB2, epidermal growth factor receptor 2; STK10, serine threonine kinase 10; PTK2B, protein tyrosine kinase 2 beta; MAP2K2, mitogen-activated protein Kinase Kinase 2; YES1, YES proto-oncogene 1 tyrosine kinase; CDK11, cyclin-dependent kinase 11; PRPF4B, PRP4 pre-mRNA processing factor 4 homolog B; BMP2K, BMP-2-inducible protein kinase isoform b; PNKP, polynucleotide kinase 3'-phosphatase; FABP5, fatty acid-binding protein 5; S100A9, S100 calcium-binding protein A9; AKR1C3, aldo-keto reductase family 1 member C3; SPRR1B, small proline-rich protein 1B; TNC, tenascin C; TGFB1, transforming growth factor, beta 1; PRDX5, peroxiredoxin 5; LCP1, lymphocyte cytosolic protein 1; PHB2, prohibitin 2; P4HB, prolyl 4-hydroxylase beta-subunit; CALML5, calmodulin-like 5; KRT, keratin; NRBF2, nuclear receptor binding factor 2; CTL1, choline transporter-like 1; K2C8, keratin, type II cytoskeletal 8; TTL1, Tubulin tyrosine ligase-like family, member 1; FGFR2, fibroblast growth factor receptor 2; DDK2, Dickkopf-2; STON2, Stonin 2; LRG1, leucine-rich alpha-2-glycoprotein 1; CSF1, colony-stimulating factor 1; PROS1, protein S; PLAT, plasminogen activator; MMP13, matrix metallopeptidase-13; GSN, gelsolin; DSG4, desmoglein 4; MXRA5, matrix-remodeling associated 5; SEMA3A, semaphorin 3A; FN1, fibronectin 1; SPARC, secreted protein acidic and rich in cysteine; DSC3, desmocollin 3; CK19, cytokeratin 19; AHCY, adenosylhomosysteinase; GSTO1, glutathione S-transferase omega 1; EIF4EBP1, eukaryotic translation initiation factor 4E binding protein 1; EIF4B, eukaryotic translation initiation factor 4B; AKT1S1, AKT1 substrate 1; CAP1, cyclase-associated protein 1; CARHSP1, calcium-regulated heat stable protein 1; G3BP, galectin-3-binding protein; FLNA, Filamin-A; NDRG1, N-myc downstream regulated gene 1; FLG2, Filaggrin-2.